natgillin/translations-raw huggingface dataset:
4a Again, slowly and gently rock the pen side-to-side side 5 times (like a windscreen wiper) (Figure J). 
4a Znova počasi in rahlo 5-krat zanihajte peresnik z ene strani na drugo (premikanje, podobno avtomobilskemu brisalcu) (Slika J).
Hold Upright & Twist to 2 
Držite pokonci in zasučite do 2
(See ‘Very common side effects' in section 4 for signs of low blood sugar). 
(Za znake nizkega krvnega sladkorja glejte "Zelo pogosti
- in combination with other diabetes medicines that are taken by mouth (such as metformin, or medicines known as sulphonylureas or thiazolidinediones), or with insulin. 
- v kombinaciji z drugimi zdravili za sladkorno bolezen, ki jih zaužijete (kot so metformin ali zdravila, imenovana sulfonilsečnine ali tiazolidindioni), ali z insulinom.
Reconstitution and administration by the patient Full instructions for reconstitution and administration to be used by the patient are provided in the Instructions for Use section of the Package Leaflet. 
Celotna navodila za pripravo in dajanje, ki jih mora uporabiti bolnik, so navedena v poglavju Navodila za uporabo v navodilih za uporabo tega zdravila.
Pen storage 
Shranjevanje peresnika
5b Push needle straight down onto the clear cartridge until you hear a “click” and feel the needle “snap” into place. 
5b Potisnite iglo naravnost navzdol na prozorni vložek, dokler ne zaslišite "klik" in začutite, da je igla "sedla" na mesto.
Twist the clear cartridge slightly in the direction of the arrows (clockwise) to complete the “click” and center the number in the window. 
Prozorni vložek rahlo zasukajte v smeri puščic (v smeri urnega kazalca), da boste dosegli "klik" in bo številka na sredi okenca.
Gastrointestinal events occurred with a higher frequency for Eperzan compared to all comparators (38% versus 32%). 
Učinki na prebavilih so bili med uporabo zdravila Eperzan pogostejši kot med uporabo vseh primerjalnih zdravil (38 % v primerjavi z 32 %).
Dispose of it as your doctor or pharmacist has instructed. 
Zavrzite ga, kot vam je naročil zdravnik ali farmacevt.
• DO NOT attach needle until instructed in Step 5. 
• NE NAMESTITE igle, dokler v 5. koraku ne dobite navodila za to.
Very common: may affect more than 1 in 10 people: 
Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov:
Intent to Treat Population (N) 
Populacija z-namenom-zdravljenja (n)
It is very important that you continue to follow any diet and lifestyle advice from your doctor while taking Eperzan. 
Zelo pomembno je, da med jemanjem zdravila Eperzan upoštevate vsa zdravnikova navodila glede diete in načina življenja.
• A clock or timer (Figure C). 
• Uro ali štoparico (Slika C) • Vsebnik za odlaganje peresnika
Therefore, patients may require a lower dose of sulphonylurea or insulin to reduce the risk of hypoglycaemia (see sections 4.2, 4.8). 
Da bi zmanjšali tveganje za hipoglikemijo, lahko bolniki potrebujejo nižji odmerek sulfonilsečnine ali insulina (glejte poglavji 4.2 in 4.8).
Eperzan lowers fasting glucose and reduces postprandial glucose excursions. 
Zdravilo Eperzan zniža glukozo na tešče in zmanjša postprandialne poraste glukoze.
Intent to Treat Population (N) HbA1c (%) 
Populacija z-namenom-zdravljenja (n) HbA1c (%)
Trace levels of albiglutide were detected in plasma of offspring. 
V plazmi mladičev so odkrili albiglutid v sledovih.
No dose adjustment is recommended for patients with hepatic impairment. 
Za bolnike z okvaro jeter ni priporočena prilagoditev odmerka.
Rare: may affect up to 1 in 1000 people: 
Redki: pojavijo se lahko pri do 1 od 1.000 bolnikov:
Insulin glargine  Metformin (with or without sulphonylurea) 
Insulin glargin ± metformin (s sulfonilsečnino ali brez nje)
DO NOT recap the needle or take the needle off the pen. 
NE NAMEŠČAJTE pokrovčka nazaj na iglo in ne odstranjujte igle s peresnika.
Dual Chamber Cartridge (DCC) composed of a Type 1 glass barrel sealed with bromobutyl rubber stoppers and a bromobutyl rubber closure disc encased in a polypropylene snap on cap. Each cartridge is assembled into a disposable single use plastic pen injector (pen). 
Vložek z dvema razdelkoma (DCC - Dual Chamber Cartridge), ki ga sestavlja valj iz stekla tipa I, zaprt z zamaški iz brombutilne gume in zapornim diskom iz brombutilne gume, vloženim v polipropilensko zaskočno zaporko.
Set a timer for 30 minutes. 
Nastavite štoparico na 30 minut.
Mortalities have not been observed in previous toxicology studies in nonlactating or non-pregnant mice, nor in pregnant mice. 
V predhodnih toksikoloških študijah miši, ki niso dojile ali niso bile breje, in pri brejih miših niso opažali umrljivosti.
Albiglutide (50 mg weekly at steady-state) had no clinically relevant effects on the steady-state pharmacokinetics of a combination oral contraceptive containing norethindrone 0.5 mg and ethinyl estradiol 0.035 mg. 
Albiglutid (50 mg na teden v stanju dinamičnega ravnovesja) ni klinično pomembno vplival na farmakokinetiko kombiniranih peroralnih kontraceptivov z 0,5 mg noretindrona in 0,035 mg etinilestradiola v stanju dinamičnega ravnovesja.
At Week 26, the mean daily dose of insulin glargine was 53 IU for Eperzan and 51 IU for lispro. 
Šestindvajseti teden je bil povprečni dnevni odmerek insulina glargina 53 i.e. z zdravilom Eperzan in 51 i.e. z insulinom lispro.
Store refrigerated at 2C to 8C. 
Shranjujte v hladilniku pri temperaturi od 2 °C do 8 °C.
Studies evaluated the use of Eperzan 30 mg and 50 mg once weekly, allowing for optional titration of Eperzan from 30 mg to 50 mg once weekly in 5 of the 8 studies. 
Študije so ocenile uporabo 30 mg in 50 mg zdravila Eperzan enkrat na teden; v 5 od 8 študij je bilo dovoljeno fakultativno titriranje zdravila Eperzan s 30 mg na 50 mg enkrat na teden.
If you do not wait the full 30 minutes the medicine may not be mixed with the water the right way. 
Če ne počakate polnih 30 minut, zdravilo še ne bo pravilno zmešano z vodo.
Eperzan 30 mg SC weekly (with uptitration to 50 mg weekly if needed) was compared to sitagliptin. 
Zdravilo Eperzan 30 mg subkutano na teden (z zvišanjem na 50 mg na teden, če je bilo potrebno) so primerjali s sitagliptinom.
No clinical studies were conducted to examine the effects of hepatic impairment on the pharmacokinetics of Eperzan. 
Kliničnih študij za ugotavljanje vplivov okvare jeter na farmakokinetiko zdravila Eperzan niso izvedli.
Atrial fibrillation/flutter occurred in 1% of patients receiving Eperzan and 0.5% of patients in the all comparators group. 
Atrijska fibrilacija/undulacija se je pojavila pri 1 % bolnikov, ki so prejemali zdravilo Eperzan, in pri 0,5 % vseh bolnikov, ki so prejemali katero od primerjalnih zdravil.
The change from baseline in weight did not differ significantly between treatment groups (see Table 4). 
Sprememba telesne mase od izhodišča se med terapevtskima skupinama ni značilno razlikovala (glejte preglednico 4).
PHARMACEUTICAL FORM AND CONTENTS Powder and solvent for solution for injection 4 pens 
FARMACEVTSKA OBLIKA IN VSEBINA Prašek in vehikel za raztopino za injiciranje 4 peresniki
If you do not wait the full 15 minutes the medicine may not be mixed with the water the right way. 
Če ne počakate polnih 15 minut, zdravilo še ne bo pravilno zmešano z vodo.
• A new needle (Figure B). 
• Novo iglo (Slika B)
The recommended dose of Eperzan is 30 mg once weekly, administered subcutaneously. 
Priporočeni odmerek zdravila Eperzan je 30 mg enkrat na teden subkutano.
Pneumonia occurred in 2% of patients receiving Eperzan compared to 0.8% of patients in the all comparators group. 
Pljučnica Pljučnica se je pojavila pri 2 % bolnikov, ki so prejemali zdravilo Eperzan, in pri 0,8 % vseh bolnikov, ki so prejemali katero od primerjalnih zdravil.
The lyophilised powder contained within the pen must be reconstituted prior to administration. 
Liofilizirani prašek v peresniku je treba pred uporabo pripraviti.
This medicinal product contains less than 1 mmol sodium (23 mg) per 0.5 ml dose, i.e. essentially “sodiumfree”. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 0,5-ml odmerek; to pomeni, da je praktično "brez natrija".
The average weekly steady state concentrations following SC administration of 30 mg or 50 mg albiglutide estimated in the population PK analyses from phase III patient studies were approximately 2.6 mcg/ml and 4.4 mcg/ml, respectively. 
Povprečna tedenska koncentracija v stanju dinamičnega ravnovesja po subkutani uporabi 30 mg ali 50 mg albiglutida, ocenjena v populacijskih farmakokinetičnih analizah v študijah III. faze pri bolnikih, je bila približno 2,6 µg/ml (30 mg) in 4,4 µg/ml (50 mg).
The efficacy of Eperzan was evaluated in a randomised, double-blind, active-controlled 52-week study in 486 patients with mild, moderate, and severe renal impairment inadequately controlled on a current regimen of diet and exercise or other antidiabetic therapy. 
52-tedenski študiji pri 486 bolnikih z blago, zmerno in hudo okvaro ledvic, neustrezno urejenih s trenutno shemo diete in telesne dejavnosti ali drugega antidiabetičnega zdravljenja.
Based on the results of population pharmacokinetic analyses that included Caucasian, African American/African, Asian and Hispanic/Non-Hispanic patients, race and ethnicity had no clinically meaningful effect on the pharmacokinetics of Eperzan clearance. 
Azijce in bolnike hispanskega/nehispanskega porekla, rasa in etnična pripadnost nista klinično pomembno vplivali na farmakokinetiko zdravila Eperzan.
Also contains: Sodium dihydrogen phosphate monohydrate, disodium phosphate, anhydrous, trehalose dihydrate, mannitol (E421), polysorbate 80, water for injections 
Vsebuje tudi: natrijev dihidrogenfosfat monohidrat, brezvodni natrijev hidrogenfosfat, trehaloza dihidrat, manitol (E421), polisorbat 80, voda za injekcije
Conditions you need to look out for: Risk of acute pancreatitis (an inflamed pancreas) Pancreatitis has been reported as an uncommon side effect. 
Stanja na katera morate biti pozorni: Tveganje za akutni pankreatitis (vnetje trebušne slinavke).
Active-controlled study versus liraglutide in combination with metformin, thiazolidinedione, or sulphonylurea (as monotherapy or dual therapy) 
Z aktivno učinkovino kontrolirana študija v primerjavi z liraglutidom v kombinaciji z metforminom, tiazolidindionom ali sulfonilsečnino (kot monoterapija ali dvotirno zdravljenje)
Use immediately after needle is attached. 
Uporabite takoj po namestitvi igle.
If you are unable to turn to position [3], throw it away and use another pen. 
Če peresnika ne morete obrniti do položaja [3], ga zavrzite in uporabite drugega.
Read all of this leaflet carefully before you start taking this medicine, as well as all the instructions including the Pen Storage and Important Warnings. 
Pred začetkom jemanja zdravila natančno preberite to navodilo in tudi vsa navodila, vključno s poglavjema
A meta-analysis of 9 clinical studies (8 major effectiveness studies and 1 phase II dose finding study) of up to 3 years duration was conducted to assess the cardiovascular safety of Eperzan (N=2,524) compared to all comparators (N=2,583) within these trials. 
faze za določitev odmerka), ki so trajale do 3 let, za oceno kardiovaskularne varnosti zdravila Eperzan (N = 2.524) v primerjavi z vsemi primerjalnimi zdravili (N = 2.583) v teh preskušanjih.
You may feel the pain going from your front (abdomen) through to your back. 
Bolečine lahko spremlja bruhanje ali pa tudi ne. Občutite lahko širjenje bolečin iz sprednjega dela (trebuha) v hrbet.
Name and address of the manufacturer responsible for batch release: 
Ime in naslov izdelovalca, odgovornega za sproščanje serij:
If you have heard and felt the injection button “click” and slowly counted to 5 before pulling the needle out of your skin, you should have received the full dose of your medicine. 
Če ste slišali in čutili, da je gumb za injiciranje "kliknil" in ste počasi prešteli do 5,
At Week 156, 77% of patients treated with Eperzan were uptitrated to 50 mg SC weekly. 
Pri 77 % bolnikov, ki so prejemali zdravilo Eperzan, je bil 156. teden odmerek zvišan na 50 mg subkutano na teden.
Treatment with Eperzan did not meet the pre-specified noninferiority margin (0.3%) against liraglutide for HbA1c (see Table 8). 
Zdravljenje z zdravilom Eperzan v primerjavi z liraglutidom ni doseglo vnaprej opredeljene meje neinferiornosti (0,3 %) za HbA1c (glejte preglednico 8).
2b Slowly and gently rock the pen side-to-side 5 times (like a windscreen wiper) (Figure H). 
2b Počasi in rahlo 5-krat zanihajte peresnik z ene strani na drugo (premikanje, podobno avtomobilskemu brisalcu) (Slika H).
Eperzan contains the active ingredient albiglutide which belongs to a group of medicines called GLP-1 receptor agonists that are used to lower blood sugar (glucose) in adults with Type 2 diabetes. 
imenovano agonisti receptorjev GLP-1, ki se uporabljajo za znižanje krvnega sladkorja (glukoze) pri odraslih s sladkorno boleznijo tipa 2.
Step 2 Mix Medicine 
2. korak Premešajte zdravilo
In a thorough QT study in healthy subjects, an increase in heart rate (6 to 8 bpm) was observed after repeat dosing with albiglutide 50 mg compared to baseline values. 
V podrobni študiji intervala QT pri zdravih preiskovancih so po ponavljajočem se odmerjanju 50 mg albiglutida opažali porast srčne frekvence (od 6 do 8 utripov na minuto) v primerjavi z izhodiščnimi vrednostmi.
• if you are taking a sulphonylurea or insulin for your diabetes, as low blood sugar (hypoglycaemia) can occur. 
• če za sladkorno bolezen jemljete kakšno sulfonilsečnino ali uporabljate insulin, ker se lahko pojavi nizek krvni sladkor (hipoglikemija).
Difference from insulin glargineb (95% CI) P value (noninferiority) Proportion Achieving HbA1c <7% Body Weight (kg) 
Sprememba po 52 tednihb Razlika od insulina glarginab (95 % IZ) Vrednost p (neinferiornost) Delež bolnikov, ki so dosegli HbA1c < 7 % Telesna masa (kg)
• Store your pens at room temperature, not to exceed 30°C, for up to 4 weeks. 
• Peresnike shranjujte pri sobni temperaturi do 30 °C in ne več kot 4 tedne.
Patients with hepatic insufficiency 
Bolniki z insuficienco jeter
This can cause your needle to block, you should continue from Step 5 to Step 6 right away. 
Po 5. koraku morate nemudoma nadaljevati s 6. korakom.
For liquids, gastric emptying t1/2 increased from 0.28 h to 0.69 h (p=0.0018). 
Za tekočine se je t1/2 praznjenja želodca podaljšal z 0,28 ure na 0,69 ure (p =
The efficacy of Eperzan was evaluated in a 32-week, randomised, open-label, liraglutide-controlled noninferiority study (N = 805). 
Učinkovitost zdravila Eperzan so ocenili v 32-tedenski randomizirani, odprti, z liraglutidom kontrolirani študiji neinferiornosti (n = 805).
What if I leave my pen for more than 15 minutes after turning the pen to the Number 2 (Step 
Kaj, če čakam več kot 15 minut po obratu peresnika na številko 2 (2. korak)?
Patients with severe renal impairment receiving Eperzan experienced a higher frequency of diarrhoea, nausea, and vomiting compared to patients with mild or moderate renal impairment. 
Okvara ledvic Bolniki s hudo okvaro ledvic, ki so prejemali zdravilo Eperzan, so imeli drisko, navzeo in bruhanje pogosteje kot bolniki z blago ali zmerno okvaro ledvic.
Treatment with Eperzan resulted in a mean weight loss for Eperzan (-0.7 kg) compared to a mean weight gain for insulin lispro (+0.8 kg) and the difference between treatment groups was statistically significant (see Table 6). 
Zdravljenje z zdravilom Eperzan je v povprečju povzročilo zmanjšanje telesne mase z zdravilom Eperzan (0,7 kg), medtem ko se je z insulinom lispro telesna masa v povprečju povečala (+0,8 kg); razlika med terapevtskima skupinama je bila statistično značilna (glejte preglednico 6).
The model-adjusted mean decrease in HbA1c from baseline with Eperzan was -0.80 (n = 125), -0.83 (n = 98), and -1.08 (n = 19) in patients with mild (eGFR 60 to 89 ml/min/1.73m2), moderate (eGFR 30 to 59 ml/min/1.73m2), and severe (eGFR <30 ml/min/1.73m2) renal impairment, respectively (see Table 9). 
Za model korigirano povprečno znižanje HbA1c v primerjavi z izhodiščem je bilo za zdravilo Eperzan -0,80 (n = 125) pri bolnikih z blago okvaro ledvic (eGFR od 60 do 89 ml/min/1,73 m2), -0,83 (n = 98) pri bolnikih z zmerno okvaro ledvic (eGFR od 30 do 59 ml/min/1,73 m2) in -1,08 (n = 19) pri bolnikih s hudo okvaro ledvic (eGFR < 30 ml/min/1,73 m2) (glejte preglednico 9).
A single dose of simvastatin (80 mg) was administered with steady-state albiglutide (50 mg weekly). 
Enkraten odmerek simvastatina (80 mg) so uporabili v stanju dinamičnega ravnovesja albiglutida (50 mg na teden).
Albiglutide did not meaningfully alter the pharmacokinetics of a single-dose of digoxin (0.5 mg) when coadministered with steady-state albiglutide (50 mg weekly). 
Albiglutid ni pomembno spremenil farmakokinetike enkratnega odmerka digoksina (0,5 mg), če je bil ta uporabljen sočasno v stanju dinamičnega ravnovesja albiglutida (50 mg na teden).
A prolonged period of observation and treatment for these symptoms may be necessary, taking into account the half-life of albiglutide (5 days). 
Zaradi razpolovnega časa albiglutida (5 dni) bi lahko bilo potrebno podaljšano opazovanje in zdravljenje teh simptomov.
There is no therapeutic experience with Eperzan in patients with type 1 diabetes mellitus and it should not be used in these patients. 
4.4 Posebna opozorila in previdnostni ukrepi Z zdravilom Eperzan ni terapevtskih izkušenj pri bolnikih s sladkorno boleznijo tipa 1; pri teh bolnikih se ga ne sme uporabljati.
The efficacy of Eperzan was evaluated in a 3-year randomised, double-blind, placebo-controlled, multicentre study (n = 296) in patients inadequately controlled on diet and exercise. 
Monoterapija Učinkovitost zdravila Eperzan so ocenili v 3-letni randomizirani, dvojno slepi, s placebom kontrolirani multicentrični študiji (n = 296) bolnikov, nezadostno urejenih z dieto in telesno dejavnostjo.
After mixing, wait 15 minutes before injection 
Po mešanju počakajte 15 minut, preden injicirate.
Non-clinical data reveal no special hazards for humans based on studies of safety pharmacology or repeatdose toxicity. 
Predklinični podatki na osnovi študij farmakološke varnosti in toksičnosti ponavljajočih se odmerkov ne kažejo posebnih tveganj za človeka.
Rock Pen Again 
Znova zanihajte peresnik
What if I leave my pen for more than 30 minutes after turning the pen to the Number 2 (Step 
Kaj, če čakam več kot 30 minut po obratu peresnika na številko 2 (2. korak)?
REMOVING BOTH NEEDLE CAPS AND INJECTING YOUR MEDICINE (STEPS 7-8) After I turn the pen to Number 3 (Step 6), there are still some small air bubbles remaining. 
KORAK) Ko peresnik obrnem na številko 3 (6. korak), je v vložku še vedno nekaj majhnih mehurčkov zraka.
After mixing, wait 30 minutes before injection 
Po mešanju počakajte 30 minut, preden injicirate.
• A new pen (Figure A). 
• Nov peresnik (Slika A)
A statistically significant decrease in body weight was observed for Eperzan compared to an increase in body weight for insulin glargine and the difference in weight change was statistically significant (see Table 7). 
Z zdravilom Eperzan so opažali statistično značilno znižanje telesne mase, z insulinom glarginom pa njeno povečanje; razlika v spremembi telesne mase je bila statistično značilna (glejte preglednico 7).
However, if you take Eperzan with sulphonylurea or insulin, you may get low blood sugar (hypoglycaemia). 
Vendar če uporabljate zdravilo Eperzan skupaj s sulfonilsečnino ali insulinom, se vam lahko pojavi nizek krvni sladkor (hipoglikemija).
GlaxoSmithKline Trading Services Limited, Currabinny, Carrigaline, County Cork, Ireland 
GlaxoSmithKline Trading Services Limited, Currabinny, Carrigaline, County Cork, Irska
4 pen needles 
4 igle za peresnik
Eperzan 30 mg SC weekly (with uptitration to 50 mg weekly at Week 6) was compared to liraglutide 1.8 mg daily (titrated up from 0.6 mg at Week 1 and 1.2 mg at Week 1 to Week 2) in patients inadequately controlled on monotherapy or combination oral antidiabetic therapy (metformin, thiazolidinedione, or sulphonylureas). 
Zdravilo Eperzan 30 mg subkutano na teden (z zvišanjem na 50 mg na teden 6. teden) so primerjali z 1,8 mg liraglutida na dan (titriranega od 0,6 mg 1. teden in 1,2 mg 1. do 2. teden) pri bolnikih, neustrezno urejenih z monoterapijo ali kombinacijo peroralnih antidiabetikov (metformin, tiazolidindion ali sulfonilsečnine).
Patients (%) Achieving HbA1c <7% Body Weight (kg) 
Bolniki (%), ki so dosegli HbA1c < 7 % Telesna masa (kg)
In patients who completed the study (52 weeks), the adjusted mean change in baseline in HbA1c was -1.0% for Eperzan (N = 121) and -0.9% for insulin lispro (N = 141). 
Pri bolnikih, ki so dokončali študijo (52 tednov) je bila korigirana povprečna sprememba HbA1c v primerjavi z izhodiščem -1,0 % za zdravilo Eperzan (N = 121) in -0,9 % za insulin lispro (N = 141).
The clinical experience in patients >75 years is very limited (see section 5.2). 
Kliničnih izkušenj z bolniki, starimi ≥ 75 let, je zelo malo
At 26 weeks, the between-treatment difference in HbA1c of 0.2% for Eperzan and insulin lispro met the pre-specified noninferiority margin (0.4%). 
Po 26 tednih je bila razlika HbA1c med zdravljenjema za zdravilo Eperzan in insulin lispro 0,2 % in je dosegla vnaprej opredeljeno mejo neinferiornosti (0,4 %).
Solvent: A clear, colourless solution. 
Vehikel: bistra, brezbarvna raztopina.
Age had no clinically relevant effect on the pharmacokinetics of albiglutide based on a population pharmacokinetic analysis of subjects aged 24-83 years (see section 4.2). 
Na podlagi populacijske farmakokinetične analize preiskovancev, starih od 24 do 83 let, starost ni klinično pomembno vplivala na farmakokinetiko albiglutida (glejte poglavje 4.2).
In patients who were treated for at least 104 weeks, the adjusted mean change in baseline in HbA1c was -0.97% for Eperzan (N = 182) and -1.04% for insulin glargine (N = 102). 
Pri bolnikih, zdravljenih vsaj 104 tedne, je bila korigirana povprečna sprememba HbA1c v primerjavi z izhodiščem -0,97 % za zdravilo Eperzan (N = 182) in -1,04 % za insulin glargin (N = 102).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON - 4 pen pack 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA - pakiranje s 4 peresniki
Compared to placebo, treatment with Eperzan resulted in statistically significant reductions from baseline in HbA1c (-0.8% for Eperzan versus -0.1% for placebo, p<0.05) and FPG (-1.3 mmol/l for Eperzan versus +0.4 mmol/l for placebo, p<0.05) at 52 weeks. 
Zdravljenje z zdravilom Eperzan je v primerjavi s placebom od izhodišča do 52. tedna statistično značilno znižalo HbA1c (-0,8 % Eperzan, -0,1 % placebo, p < 0,05) in glukozo v plazmi na tešče (-1,3 mmol/l Eperzan in +0,4 mmol/l placebo, p < 0,05).
Insulin lispro Insulin glargine ( 20 units per day) 
Insulin lispro Insulin glargin (≥ 20 enot na dan)
Other side effects reported with Eperzan 
Drugi neželeni učinki, opisani z zdravilom Eperzan
No overall differences in glycaemic effectiveness or body weight were observed across demographic subgroups (age, gender, race/ethnicity, duration of diabetes). 
Po demografskih podskupinah (starost, spol, rasa/etnična pripadnost, trajanje sladkorne bolezni) v celoti niso opažali razlik v učinkovitosti, kar zadeva glikemijo, ali v telesni masi.
The most common events leading to discontinuation of Eperzan were reactions at the injection site and GI related events, each 
Najpogostejši neželeni učinki, ki so povzročili prenehanje uporabe zdravila Eperzan, so bile reakcije na mestu injiciranja in učinki na prebavilih; enih in drugih je bilo < 2 %.
The change from baseline in HbA1c at the 6 month timepoint was also statistically significant for the 30 mg (0.9%) and 50 mg (1.1%) weekly doses of Eperzan (see Table 2). 
Statistično značilni sta bili tudi spremembi izhodiščnega HbA1c po 6 mesecih, tako za tedenski odmerek 30 mg (0,9 %) kot 50 mg (1,1 %) zdravila Eperzan (glejte preglednico 2).
Step 4 Rock pen and check medicine 
4. korak Zanihajte peresnik in preverite zdravilo
IMPORTANT: You may hear a “click” when you first start twisting the cartridge from [2] to [3]. 
POMEMBNO: Ko boste začeli sukati vložek od [2] proti [3], boste morda zaslišali "klik".
How to use Eperzan 
Kako uporabljati zdravilo Eperzan